Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma

Biomaterials

Volumn 33, Issue 30, 2012, Pages 7594-7604

  Shi, Lili ^a   Tang, Cui ^a   Yin, Chunhua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antitumor efficacy; Chitosan nanoparticles; Glycyrrhizin; Hepatocellular carcinoma; Paclitaxel; Targeted drug delivery

Indexed keywords

ANTI-TUMOR EFFICACY; CHITOSAN NANOPARTICLES; GLYCYRRHIZIN; HEPATOCELLULAR CARCINOMA; PACLITAXEL; TARGETED DRUG DELIVERY;

CHITOSAN; DRUG DELIVERY; ENCAPSULATION; PLASMA STABILITY; TOXICITY; TUMORS;

NANOPARTICLES;

CHITOSAN; GLYCYRRHIZIC ACID; NANOPARTICLE; O CARBOXYMETHYL CHITOSAN NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTACT ANGLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG RELEASE; ENCAPSULATION; FEMALE; HEART; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; KIDNEY; LIVER CELL CARCINOMA; LUNG; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; GLYCYRRHIZIC ACID; HUMANS; LIVER; LIVER NEOPLASMS; MICE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; RHODAMINES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84865000013     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.072     Document Type: Article

References (29)

1. Ma S.M., Jiao B.Z., Liu X., Yi H.Q., Kong D.J., Gao L., et al. Anti-tumor treatment: approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev 2010, 36(2):157-163.
2. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7(11):653-664.
3. Kean T., Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliver Rev 2010, 62(1):3-11.
4. Park J.H., Saravanakumar G., Kim K., Kwon I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliver Rev 2010, 62(1):28-41.
5. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliver Rev 2008, 60(15):1615-1626.
6. Negishi M., Irie A., Nagata N., Ichikawa A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta 1991, 1066(1):77-82.
7. Ismair M.G., Stanca C., Ha H.R., Renner E.L., Meier P.J., Kullak-Ublick G.A. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol Res 2003, 26(4):343-347.
8. Mao S., Hou S., He R., Zhang L., Wei D., Bi Y., et al. Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes. World J Gastroenterol 2005, 11(20):3075-3079.
9. Lin A., Liu Y., Huang Y., Sun J., Wu Z., Zhang X., et al. Glycyrrhizin surface modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharmaceut 2008, 359(1-2):247-253.
10. Lin A., Chen J., Liu Y., Deng S., Wu Z., Huang Y., et al. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm 2009, 35(11):1348-1355.
11. Cui F., Qian F., Yin C. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharmaceut 2006, 316(1-2):154-161.
12. Xu L.C., Siedlecki C.A. Effects of surface wettability and contact time on protein adhesion to biomaterial surfaces. Biomaterials 2007, 28(22):3273-3283.
13. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31(13):3657-3666.
14. Guo D., Xu C., Quan J., Song C., Jin H., Kim D.D., et al. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials 2009, 30(27):4777-4785.
15. Danhier F., Lecouturier N., Vroman B., Jerome C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133(1):11-17.
16. Berlin J.M., Leonard A.D., Pham T.T., Sano D., Marcano D.C., Yan S.Y., et al. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel. ACS Nano 2010, 4(8):4621-4636.
17. Farokhzad O.C., Cheng J.J., Teply B.A., Sherifi I., Jon S.Y., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006, 103(16):6315-6320.
18. Wang X., Li J., Wang Y.Q., Cho K.J., Kim G., Gjyrezi A., et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3(10):3165-3174.
19. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9(5):1909-1915.
20. Tian Q., Zhang C.N., Wang X.H., Wang W., Cha R.T., Wang C.H., et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 2010, 31(17):4748-4756.
21. Liu Y., Li K., Pan J., Liu B., Feng S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials 2010, 31(2):330-338.
22. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008, 69(1):1-9.
23. Chiba N., Ueda M., Shimada T., Jinno H., Watanabe J., Ishihara K., et al. Development of gene vectors for pinpoint targeting to human hepatocytes by cationically modified polymer complexes. Eur Surg Res 2007, 39(1):23-34.
24. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8(7):543-557.
25. Zhu Z., Li Y., Li X., Li R., Jia Z., Liu B., et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 2010, 142(3):438-446.
26. Yu D., Lu Q., Xie J., Fang C., Chen H. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31(8):2278-2292.
27. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
28. Doucette M.M., Stevens V.L. Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. J Nutr 2001, 131(11):2819-2825.
29. Ghaghada K.B., Saul J., Natarajan J.V., Bellamkonda R.V., Anapragada A.V. Folate targeting of drug carriers: a mathematical model. J Control Release 2005, 104(1):113-128.